Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0KX6E
|
||||
| Former ID |
DNCL003480
|
||||
| Drug Name |
DI-Leu16-IL2
|
||||
| Indication | B-cell lymphoma [ICD9: 202.8; ICD10:C85.1] | Phase 1/2 | [1] | ||
| Company |
Alopexx Oncology
|
||||
| Target and Pathway | |||||
| Target(s) | B-lymphocyte antigen CD20 | Target Info | Modulator | [2] | |
| KEGG Pathway | Hematopoietic cell lineage | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01874288) Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL. U.S. National Institutes of Health. | ||||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 599668). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.